Lirafugratinib, an oral FGFR2 inhibitor, receives FDA Priority Review for advanced cholangiocarcinoma with FGFR2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results